# Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study

> **NCT02632903** · PHASE2 · WITHDRAWN · sponsor: **Children's Hospital of Eastern Ontario**

## Conditions studied

- Osteoporosis
- Osteonecrosis
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT02632903
- **Lead sponsor:** Children's Hospital of Eastern Ontario
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-10
- **Primary completion:** 2018-03
- **Final completion:** 2018-08-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** While the clinical need for and the scientific merit remain valid, this regulated drug trial was not feasible logistically due to limited funds.
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632903, "Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02632903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*